A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.

PHASE2CompletedINTERVENTIONAL
Enrollment

2,288

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Patients With Metabolic Syndrome
Interventions
DRUG

Fenofibrate /Metformin

fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)

DRUG

Fenofibrate /Metformin

fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)

DRUG

Fenofibrate /Metformin

fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)

DRUG

Fenofibrate /Metformin

fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)

DRUG

Fenofibrate /Metformin

fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)

DRUG

Fenofibrate /Metformin

fenofibrate placebo + metformin 850 mg bid (F0-M1700)

DRUG

Placebo

Placebo

Trial Locations (101)

Unknown

Site 013, Calgary

Site 019, Calgary

Site 007, Chicoutimi

Site 024, Halifax

Site 004, Hamilton

Site 012, Kingston

Site 017, Longueuil

Site 009, Montague

Site 001, Montreal

Site 015, Montreal

Site 003, Québec

Site 025, Sainte-Foy

Site 026, Sainte-Foy

Site 021, Sherbrooke

Site 010, St. John's

Site 020, St. John's

Site 022, St. John's

Site 006, Ste-Foy

Site 016, Toronto

Site 005, Vancouver

Site 011, Victoria

Site 090, Hus

Site 091, Jakobstad

Site 095, Jyväskylä

Site 092, Mikkeli

Site 096, Närpes

Site 094, Vaasa

Site 190, Budapest

Site 191, Budapest

Site 193, Budapest

Site 199, Budapest

Site 202, Budapest

Site 204, Budapest

Site 203, Debrecen

Site 200, Gyöngyös

Site 201, Győr

Site 198, Gyula

Site 197, Miskolc

Site 196, Pécs

Site 194, Szeged

Site 192, Székesfehérvár

Site 205, Szombathely

Site 195, Veszprém

Site 074, Catanzaro

Site 077, Chieti Scalo

Site 075, Padua

Site 076, Padua

Site 073, Palermo

Site 072, Perugia

Site 070, Treviglio Bergamo

Site 044, Almere Stad

Site 040, Amsterdam-Zuidoost

Site 054, Den Helder

Site 057, Dordrecht

Site 042, Eindhoven

Site 045, Groningen

Site 052, Groningen

Site 041, Hoorn

Site 046, Leiden

Site 047, Rotterdam

Site 051, Rotterdam

Site 043, Sliedrecht

Site 055, Tiel

Site 053, Veldhoven

Site 048, Velp

Site 056, Velp

Site 049, Zoetermeer

Site 060, Zwijndrecht

Site 117, Elverum

Site 114, Hobol

Site 111, Horten

Site 110, Oslo

Site 112, Oslo

Site 113, Oslo

Site 118, Oslo

Site 115, Skedsmokorset

Site 130, Brodnowski

Site 139, Chrzanów

Site 134, Gdansk

Site 132, Katowice

Site 131, Kielce

Site 135, Olsztyn

Site 138, Ul. Ziolowa

Site 133, Warsaw

Site 220, Brasov

Site 210, Bucharest

Site 211, Bucharest

Site 212, Bucharest

Site 214, Bucharest

Site 218, Bucharest

Site 219, Bucharest

Site 215, Cluj-Napoca

Site 213, Craiova

Site 217, Iași

Site 216, Suceava

Site 153, Gothenburg

Site 154, Kristianstad

Site 150, Linköping

Site 155, Lund

Site 152, Stockholm

Site 151, Umeå

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00703755 - A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome. | Biotech Hunter | Biotech Hunter